Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Aulitzky

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Annals of Hematology|October 6, 1998
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy appliedT Fischer, A Neubauer, J Mohm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Annals of Hematology|October 6, 1998
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy appliedT Fischer, A Neubauer, J Mohm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Pageof 7